{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', \"7. Prior history of suicide attempt at any time in the subject's lifetime prior to signing the\", 'informed consent, or major psychiatric illness requiring hospitalization within the last 3', 'years prior to signing the informed consent.', '8. Subjects with severe renal impairment, defined by eGFR (estimated glomerular filtration', 'rate) or CLcr (creatinine clearance) less than 30 mL/min, are also categorized as having', 'Stage 4 Chronic Kidney Disease (CKD), and are excluded from the study.', '9. Malignancy or history of malignancy or myeloproliferative or lymphoproliferative', 'disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell', 'in situ skin carcinomas.', '10. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant', 'viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections', 'must have been completed and the infection cured, at least 4 weeks prior to Screening', 'and no new or recurrent infections prior to the Baseline Visit.', '11. Subject has received a live vaccine within 3 months of baseline or plans to do so during', 'study.', '12. Subject is a pregnant or breastfeeding (lactating) woman.', '13. Subject has used topical therapy within 2 weeks of randomization (including, but not', 'limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus,', 'pimecrolimus, anthralin/dithranol, or moisturizers which contain urea or salicylic acid).', 'Use of phototherapy within 4 weeks prior to randomization. Use of conventional', 'systemic therapy or systemic corticosteroids within 4 weeks prior to randomization,', 'except for conditions other than psoriasis or psoriatic arthritis. Use of biologic therapy', 'within 5 pharmacokinetic half-lives.', '14. Prior treatment with apremilast, or participation in a clinical study, involving apremilast.', '15. Subject has any condition that confounds the ability to interpret data from the study.', '16. Subject has history of allergy or hypersensitivity to any components of the IP (including', 'placebo).', '17. Subject has rare hereditary problem of galactose intolerance, lapp lactase deficiency or', 'glucose-galactose malabsorption.', 'Confidential and Proprietary', '28', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '5.', 'TABLE OF EVENTS', 'Table 3:', 'Table of Events', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phaseb', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ET\u00b0', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', '56 weeks (or 4 weeks after', 'Week', 'days', '(Day 1)', '( 3 days)', '( 3 days)', '( 3 days)', '(= 4 days)', '( 4 days)', '( 4 days)', '(= 4 days)', 'study discontinuation)', 'Informed consente', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Inclusion/Exclusion', 'X', 'X', '-', '-', '-', '-', '-', '-', '-', '-', 'criteria', 'Demographics', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Medical history', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Prior / concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'medications or therapies', 'Clinical and Laboratory Assessments', 'Adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy test and', '-', '-', 'X', 'X', '-', '-', '-', '-', '-', 'X', 'contraception education', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'Height', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Weight', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'Waist Circumference', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Body Mass Index', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Physical Examination', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Clinical laboratory', '-', '-', 'X', 'X', '-', '-', 'X', '-', 'X', 'X', 'evaluations-h,', 'Confidential and Proprietary', '29', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 3:', 'Table of Events (Continued)', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phase', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ETC', '56 (or 4 weeks after study', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', 'discontinuation)', 'Week', 'days', '(Day 1)', '(3 days)', '( 3 days)', '(=3 days)', '( 4 days)', '( 4 days)', '( 4 days)', '( 4 days)', 'Health-related Quality of Life and Efficacy Assessments', 'DLQI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'sPGA of Visible', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Location', 'ScPGAk', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Nail Assessment', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'NAPSI', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Modified sPGA-Gk', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'PPPGAK', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Itch NRS', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Skin Discomfort/Pain', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'VAS', 'PASI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'BSA', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'EQ-5D', '-', 'X', '-', '-', 'X', '-', '-', '-', 'X', '-', 'PNQ', '-', 'X', '-', '-', '-', '-', '-', '-', '-', '-', 'PBQ', '-', '-', '-', 'X', 'X', '-', 'X', '-', 'X', '-', 'WPAI: PSO', '-', 'X', '-', '-', 'X', '-', '-', '-', 'X', '-', 'Photography\"', '-', 'X', '-', '-', 'X', '-', 'X', '-', 'X', '-', 'Confidential and Proprietary', '30', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}